Company intelligence / Profile preview
Shine Out Bio Technology
Likely Taichung or Taipei, Taiwanshineout.com.tw ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Lead oncology programs (SOA101, SOB100/SOB101) entering or preparing for first-in-human Phase 1/2 studies in 2025; preclinical data demonstrates high tumor targeting and reduced side effects through exosome-mediated delivery
- Therapeutic areas
- OncologyNeurology
- Modalities
- Exosome-based therapyNanobody therapyTrispecific antibody
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
Collaborative technology development with China Medical University (CMU) Healthcare Systemglobal research partnerships with Kyoto University
Beyond the preview
Go deeper on Shine Out Bio Technology.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Shine Out Bio Technology.